Correlation Between Abcellera Biologics and Aligos Therapeutics

Can any of the company-specific risk be diversified away by investing in both Abcellera Biologics and Aligos Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Abcellera Biologics and Aligos Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Abcellera Biologics and Aligos Therapeutics, you can compare the effects of market volatilities on Abcellera Biologics and Aligos Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Abcellera Biologics with a short position of Aligos Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Abcellera Biologics and Aligos Therapeutics.

Diversification Opportunities for Abcellera Biologics and Aligos Therapeutics

0.64

Correlation Coefficient

Abcellera Biologics  Aligos Therapeutics

Poor diversification

The 3 months correlation between Abcellera and Aligos is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Abcellera Biologics and Aligos Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aligos Therapeutics and Abcellera Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Abcellera Biologics are associated (or correlated) with Aligos Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aligos Therapeutics has no effect on the direction of Abcellera Biologics i.e., Abcellera Biologics and Aligos Therapeutics go up and down completely randomly.

Pair Corralation between Abcellera Biologics and Aligos Therapeutics

Given the investment horizon of 90 days Abcellera Biologics is expected to generate 0.64 times more return on investment than Aligos Therapeutics. However, Abcellera Biologics is 1.56 times less risky than Aligos Therapeutics. It trades about -0.05 of its potential returns per unit of risk. Aligos Therapeutics is currently generating about -0.26 per unit of risk. If you would invest  299.00  in Abcellera Biologics on December 27, 2024 and sell it today you would lose (57.00) from holding Abcellera Biologics or give up 19.06% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Abcellera Biologics  vs.  Aligos Therapeutics

Abcellera Biologics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Abcellera Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Aligos Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Aligos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Abcellera Biologics and Aligos Therapeutics

The main advantage of trading using opposite Abcellera Biologics and Aligos Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Abcellera Biologics position performs unexpectedly, Aligos Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aligos Therapeutics will offset losses from the drop in Aligos Therapeutics' long position.

The idea behind Abcellera Biologics and Aligos Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.